AyuVis Research, Inc.
Small-molecule therapeutics for respiratory infections and ARDS
- Sector
- Biotech
- Headquarters
- FORT WORTH, TX
- Founded
- 2018
- Latest Form D
- $745K, Oct 2019
- Total capital
- $5.2M
- Federal grants
- $4.3M
- 7 awards · 2017–2026
- Rank in peer group#210 of 514
- Private capital raised
- $965K
- 2 Form D · last Oct 2019
- 85 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 3
- 15 pending · first 2022
- Rank in peer group#109 of 514
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase II · Phase 1 Safety, Pharmacokinetic study followed by Phase 2a Proof-of-Concept study of AVR-48, a small molecule macrophage modulator to prevent bronchopulmonary dysplasia in neonates$360K
- Federal grantHealth and Human S · Phase II · Phase 1 Safety, Pharmacokinetic study followed by Phase 2a Proof-of-Concept study of AVR-48, a small molecule macrophage modulator to prevent bronchopulmonary dysplasia in neonates$712K
- Federal grantHealth and Human S · Phase II · Phase 1 Safety, Pharmacokinetic study followed by Phase 2a Proof-of-Concept study of AVR-48, a small molecule macrophage modulator to prevent bronchopulmonary dysplasia in neonates$895K
- Federal grantHealth and Human S · Phase II · A novel approach for prevention of Bronchopulmonary dysplasia in at-risk pre-term infants$204K
- Federal grantHealth and Human S · Phase II · A novel approach for prevention of Bronchopulmonary dysplasia in at-risk pre-term infants$702K
- Federal grantHealth and Human S · Phase II · A novel approach for prevention of Bronchopulmonary dysplasia in at-risk pre-term infants$1.1M
- Private capital raisedForm D · SEC · 2nd filing$745K
- Private capital raisedForm D · SEC · 1st filing$220K
Show 1 earlier federal award
- Federal grantHealth and Human S · Phase I · Novel multifunctional oligosaccharide for treating sepsis and severe sepsis.$274K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Federal first
16months
from AyuVis Research, Inc.’s first federal award to its first private round.
- First federal award · Jan 2017
- Health and Human S · $274K
- First Form D · May 2018
- $220K · 1st Form D
- Awards before first raise
- 1 award
An association in public records, not a cause or a prediction.
Standing among 514 peers
Line = medianBiotech · Molecule
- Federal grants#210 · top 41%
- Granted patents#109 · top 21%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Suchismita AcharyaResearcherExecutive Officer, DirectorLinked by 3 patents · $4.3M in grants as PI
- Beamon Dennis AgarwalExecutive OfficerNamed in SEC Form D filings
- Dwight M HortonExecutive OfficerNamed in SEC Form D filings
- Gagan M AcharyaExecutive Officer, DirectorNamed in SEC Form D filings
- Russell M BromleyExecutive OfficerNamed in SEC Form D filings
- Stella M RobertsonDirectorNamed in SEC Form D filings
Show all 7 people
- William Dennis DeanExecutive OfficerNamed in SEC Form D filings
What it has protected
USPTO · 3 granted of 18- PendingNovel Immunodulating Small MoleculesUSPTOApplication 19570439
- GrantedNovel Immunodulating Small MoleculesUSPTOUS 12,594,286
- PendingCompositions And Methods For The Stimulation Of Intermediate Macrophages And Treatments TherewithUSPTOApplication 19194559
Show all 18 patent records
- Novel Immunodulating Small MoleculesJul 23, 2026 · Application 19570439Pending
- Novel Immunodulating Small MoleculesApr 7, 2026 · US 12,594,286Granted
- Compositions And Methods For The Stimulation Of Intermediate Macrophages And Treatments TherewithOct 30, 2025 · Application 19194559Pending
- Compositions And Methods For The Treatment Of Bronchopulmonary Dysplasia (bpd) And Bpd-associated Pulmonary HypertensionOct 14, 2025 · US 12,440,471Granted
- Chitin Analogs For The Treatment Of Kidney DiseasesAug 4, 2022 · Application 17591280Pending
- Novel Immunodulating Small MoleculesJun 21, 2022 · US 11,364,253Granted
- Compositions And Therapeutic MethodsMay 12, 2022 · Application 17525060Pending
- Compositions And Methods For The Treatment Of Bronchopulmonary Dysplasia (bpd) And Bpd-associated Pulmonary HypertensionApplication 63227819Pending
- Chitin Analogs For The Treatment Of Kidney DiseasesApplication 63145666Pending
- Novel Immunodulating Small MoleculesApplication PCTUS2019040313Pending
- Novel Immunomodulating Small MoleculesApplication 62693023Pending
- Novel Compositions And Therapeutic MethodsApplication PCTUS2017024908Pending
- Compositions And Methods For The Stimulation Of Intermediate Macrophages And Treatments TherewithApplication PCTUS2025027022Pending
- Compositions And Methods For The Stimulation Of Intermediate Macrophages And Treatments TherewithApplication 63640552Pending
- Novel Immunodulating Small MoleculesApplication PCTUS2023022481Pending
- Novel Compositions And Therapeutic MethodsApplication PCTUS2022079624Pending
- Compositons And Methods For The Treatment Of Bronchopulmonary Dysplasia (bpd) And Bpd-associated Pulmonary HypertensionApplication PCTUS2022038426Pending
- Chitin Analogs For The Treatment Of Kidney DiseasesApplication PCTUS2022014919Pending
Related companies, and why
- OPTIKIRA, LLCSimilar federal contract value in Biotech · null in contracts
- AMERICAN LIFE SCIENCE PHARMACEUTICALS, INC.Similar federal contract value in Biotech · null in contracts
- 7 Hills Pharma LLCSimilar federal contract value in Biotech · null in contracts
- EPOCH BIOTECH, LLCSimilar federal contract value in Biotech · null in contracts
- Galera Therapeutics Inc.Similar federal contract value in Biotech · null in contracts
- REVERAGEN BIOPHARMA, INC.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .